Log In
Print this Print this

AMG 232

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionMDM2 inhibitor
Molecular Target Mdm2 p53 binding protein homolog (MDM2) (HDM2)
Mechanism of ActionMdm2 p53 binding protein homolog (MDM2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today